Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.
Ascendis Pharma A/S (NASDAQ: ASND) is a global biopharmaceutical company that develops therapies using its proprietary TransCon technology platform. This news page aggregates company announcements, clinical updates, financial results, and regulatory milestones that Ascendis discloses through press releases and regulatory channels.
Readers can follow developments related to Ascendis’ commercial products and pipeline, including YORVIPATH (TransCon PTH) for adults with hypoparathyroidism and SKYTROFA (TransCon hGH) for pediatric and adult growth hormone deficiency. News items also cover investigational programs such as TransCon CNP for children with achondroplasia, combination therapy with TransCon CNP and TransCon hGH in the COACH trial, and TransCon IL-2 β/γ in late-line platinum-resistant ovarian cancer.
Updates frequently include information on Phase 2 and Phase 3 clinical trial results, publication of pivotal data in peer-reviewed journals, submissions and reviews of New Drug Applications and Marketing Authorisation Applications, and presentations at major medical and investor conferences. Financial news, such as quarterly results, revenue contributions from YORVIPATH and SKYTROFA, and commentary on the company’s progress toward its long-term vision, is also reported.
Investors and observers can use this page to monitor how Ascendis advances its TransCon-based portfolio across endocrinology, rare diseases, and oncology, as well as to track collaboration news involving partners in regions such as Greater China and Japan. For those following ASND stock, the news flow provides context on the company’s operational performance, regulatory interactions, and clinical milestones over time.
Ascendis Pharma (Nasdaq: ASND) announced two key presentations at ENDO 2025, scheduled for July 12-15, 2025, in San Francisco. The presentations will showcase important clinical data from their Endocrinology Rare Disease portfolio.
Dr. Aliya Khan will present Week 156 data from the Phase 3 PaTHway Trial of TransCon® PTH in adults with hypoparathyroidism, demonstrating long-term safety, efficacy, and improved renal function. Additionally, Dr. Carlos Bacino will present Week 52 safety and tolerability data from the pivotal ApproaCH Trial of TransCon® CNP in children with achondroplasia.
Ascendis Pharma (ASND) announced positive Week 52 data from its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia. The double-blind placebo-controlled trial, involving 84 children aged 2-11 years, demonstrated superior annualized growth velocity compared to placebo. The drug showed a favorable safety profile with no treatment-related serious adverse events, symptomatic hypotension, fractures, or bone age acceleration.
Key improvements were observed in bone morphometry, including better lower limb alignment, proportional growth, and increased spinal canal dimensions. The trial featured a 2:1 randomization ratio (TransCon CNP:placebo) for 52 weeks, followed by an open-label extension period. The results support the company's goal to provide benefits beyond linear growth and potentially reduce future complications associated with achondroplasia.
Ascendis Pharma (NASDAQ: ASND) released promising 4-year data from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism. The study demonstrated sustained efficacy with 95% patient retention (56 of 59 patients) at Week 214.
Key findings include: - 98% of patients maintained normal albumin-adjusted serum calcium levels - 93% remained independent from conventional therapy - 67.8% showed clinically meaningful improvement in kidney function (eGFR) - Bone turnover markers stabilized above baseline - Bone mineral density stayed within normal range
The treatment was well-tolerated with mostly mild to moderate adverse events, no serious treatment-related adverse events, and no treatment-related discontinuations.
Ascendis Pharma (Nasdaq: ASND) has scheduled its first quarter 2025 financial results announcement and business update for Thursday, May 1, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day.
Interested participants can access the live webcast or register for the teleconference through the company's website. A replay will be available in the Investors & News section at investors.ascendispharma.com for 30 days following the event.
Ascendis Pharma (ASND) has submitted a New Drug Application (NDA) to the FDA for TransCon CNP (navepegritide) to treat children with achondroplasia. The submission is supported by data from three randomized, double-blind, placebo-controlled clinical trials with up to three years of open-label extension data.
The treatment, administered once weekly, is designed as a prodrug of C-type natriuretic peptide (CNP) that provides continuous exposure to receptors throughout the body. Clinical data showed multiple benefits including:
- Increased growth velocity
- Reduced health-related burden
- Stronger muscle function
- Straightening of abnormal leg bowing in most treated children
The company plans to submit a Marketing Authorisation Application (MAA) to the European Medicines Agency during Q3 2025.